Back to Search

The CAROLYN Trial: Lisocabtagene Maraleucelas First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

  • Protocol Number: 202510060
  • Principal Investigator: Ghobadi, Armin
  • Cancer Types: Gene & Cellular Immunotherapy, Lymphoma

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

Protocol Interventions

Drug: Rituximab, Drug: Methotrexate, Drug: Procarbazine, Drug: Temozolomide, Biological: Liso-cel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Calcium folinate